Vanda Pharmaceuticals Announces Participation at September 2026 Investor Conferences
Vanda Pharmaceuticals Announces Participation at September 2026 Investor Conferences
PR Newswire
WASHINGTON, Sept. 2, 2026
WASHINGTON, Sept. 2, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the company will participate at the following upcoming investor conferences in September 2026:
The Wells Fargo 21st Annual Healthcare Conference in Boston on Tuesday, September 8, 2026.
The 2026 Cantor Global Healthcare Conference in New York City on Friday, September 11, 2026. A corporate presentation is scheduled for 8 a.m. Eastern Time.
The H.C. Wainwright 28th Annual Global Investment Conference in New York City on Tuesday September 15, 2026. A corporate presentation is scheduled for 10 a.m. Eastern Time.
The Morgan Stanley 24th Annual Global Healthcare Conference in New York City on Wednesday, September 16, 2026.
The corporate presentations given at the 2026 Cantor Global Healthcare Conference and H.C. Wainwright 28th Annual Global Investment Conference may be accessed live on Vanda's corporate website, www.vandapharma.com. Investors should click on the Investors tab and follow the link under Recent Events. Investors are advised to go to the conference website at least 15 minutes early to register, download, and install any necessary software or presentations. A link to the archived conference will be available on Vanda's website for a period of approximately 30 days.
About Vanda Pharmaceuticals Inc.
Vanda is a leading global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients. For more on Vanda Pharmaceuticals Inc., please visit www.vandapharma.com and follow us on X @vandapharma.
Corporate Contact:
Kevin Moran
Senior Vice President, Chief Financial Officer and Treasurer
Vanda Pharmaceuticals Inc.
202-734-3400
pr@vandapharma.com
Jim Golden / Jack Kelleher / Dan Moore
Collected Strategies
VANDA-CS@collectedstrategies.com
SOURCE Vanda Pharmaceuticals Inc.
The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
4 Stocks to Buy for the Long-Term While They’re Still Undervalued
Why This Vanguard ETF Is One of the Best
6 ETFs To Diversify Away From AI
The Best AI Stocks to Buy Now
United States